HLP003 nears phase III readout for adjunctive MDD
Help advancing HLP003 in phase III for adjunctive major depressive disorder, with top-line data expected in Q4 2026 and an NDA filing targeted for 2028.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.